Tools
Stock profile

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)

CRL · Latest close $333.25 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$333.25
As of Nov 18, 2026
Tracked funds holding
4 of 149
2026 Q2 13F filings
Opened / added
2 / 2
vs previous quarter
Trimmed / exited
1
vs previous quarter

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) is held by 4 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds opening new positions, 2 funds adding, and 1 fund trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($3.0K bought vs $19.5M sold). Latest close $333.25 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Oct 22, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-19.5M
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Ariel Investments · Oakmark Funds · Perceptive Advisors — 4 tracked funds hold CRL. See all holders.

Insider and Congress activity

Insiders bought on the open market (1 purchase, $3.0K) vs 4 sales ($19.5M). Latest buy: Sep 30, 2026. Insider trading

Often held alongside

ICON PLC (ICLR) · IQVIA HOLDINGS INC. (IQV) · Medpace Holdings, Inc. (MEDP) · INCYTE CORP (INCY) · VSE CORP (VSEC) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Ariel Investments3.41%1,506,185ADDED (+4.3%) Q3 filed Nov 13
Oakmark Funds0.67%2,241,144ADDED (+4.1%) Q3 filed Nov 16
Perceptive Advisors0.48%140,000NEW Q3 filed Nov 16
SRS Investment Management0.39%187,384NEW Q3 filed Nov 16
Maverick Capital——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +45.0% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

376.1088.702024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding567 of 8,857 filers
Long-only filers among them566
Change vs 2026 Q1+17 net · 527 entered · 510 exited
Shares reported, all filers56,355,579
Reported value, all filers$12.2B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustryServices-Commercial Physical & Biological Research (SIC 8731)
Revenue · FY2025$4.0B
Net income · FY2025$-144.3M
Total assets · FY2025$7.1B
Shares outstanding47,738,872
Market cap (at latest close)$15.9B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 25, 2026.

Short interest

Shares short · Oct 15, 20262,834,023
Share of shares outstanding5.94%
Days to cover2.90

Shares short at recent settlements — Jul 31, 2026: 3.4M · Aug 14, 2026: 2.4M · Aug 31, 2026: 2.5M · Sep 15, 2026: 2.2M · Sep 30, 2026: 2.9M · Oct 15, 2026: 2.8M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 25, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 2K · Aug 14, 2026: 2K · Aug 31, 2026: 55 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 25, 2026.

Insider trading · Form 4

1 insider bought on the open market in the last 90 days (1 purchase, $3.0K), against 4 sales by 2 insiders ($19.5M). Latest buy: Sep 30, 2026.

CEO/CFO bought

Source: SEC Form 4 filings. Open-market transactions only.

Latest open-market buyTransaction pricePrice change since disclosure
Coleman Glenn · 10 shares on Sep 30, 2026 · filed Oct 2, 2026$297.43+6.9% (close Oct 5, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Oct 5, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Oct 22, 2026FOSTER JAMES CSell24,042$350.00$8.4MSEC filing
Oct 21, 2026Parisotto Shannon MCEVP, Disc & Safety AssessmentSell2,156$344.41$742.5KSEC filing
Oct 5, 2026Parisotto Shannon MCEVP, Disc & Safety AssessmentSell981$308.44$302.6KSEC filing
Sep 30, 2026Coleman GlennEVP & Chief Financial OfficerBuy10$297.43$3.0KSEC filing
Aug 25, 2026FOSTER JAMES CSell33,561$300.00$10.1MSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Oct 5, 2026Parisotto Shannon MOfficer981$308.6KOct 5, 2026SEC filing
Aug 25, 2026FOSTER JAMES CDirector33,561$10.1MAug 25, 2026SEC filing
Aug 19, 2026Parisotto Shannon MOfficer2,039$599.7KAug 19, 2026SEC filing
Aug 18, 2026Nancy C AndrewsDirector573$163.3KAug 18, 2026SEC filing
Aug 11, 2026Parisotto Shannon MOfficer3,714$1.0MAug 11, 2026SEC filing
Aug 11, 2026Girshick BirgitOfficer, CEO & President6,500$1.8MAug 11, 2026SEC filing
Aug 10, 2026FOSTER JAMES CDirector28,733$7.9MAug 10, 2026SEC filing
Aug 6, 2026Victoria CreamerOfficer4,179$1.1MAug 6, 2026SEC filing
Aug 6, 2026Michael KnellOfficer6,645$1.7MAug 6, 2026SEC filing
Aug 5, 2026Parisotto Shannon MOfficer5,046$1.3MAug 5, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Sep 8, 2026FMR LLCSC 13G/A4,865,628.1310.2%Aug 31, 2026SEC filing
Aug 13, 2026Invesco Ltd.SC 13G2,984,7856.2%Jun 30, 2026SEC filing
Aug 6, 2026FMR LLCSC 13G/A4,239,751.478.8%Jun 30, 2026SEC filing
May 6, 2026Invesco Ltd.SC 13G/A2,397,2524.9%Mar 31, 2026SEC filing
May 6, 2026FMR LLCSC 13G3,456,244.727.0%Mar 31, 2026SEC filing
Apr 29, 2026Vanguard Capital ManagementSC 13G3,634,3767.4%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 12, 2026Invesco Ltd.SC 13G2,696,1505.5%Dec 31, 2025SEC filing
Feb 10, 2026Wellington Management Group LLPSC 13G/A1,749,2133.6%Dec 31, 2025SEC filing
Nov 14, 2025NOMURA HOLDINGS INCSC 13G/A807,9231.6%Sep 30, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Services-Commercial Physical & Biological Research (SIC 8731). No standing committee maps to this industry under the site’s jurisdiction rule — see Methodology.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 13 Lobbying Disclosure Act filings named this company as client, 2019–2026; most common issues: Medical/Disease Research/Clinical Labs (5), Health Issues (3), Food Industry (safety, labeling, etc.) (3).

Federal contracts: $318.7M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$54.7M
FY2022$61.1M
FY2023$45.5M
FY2024$24.5M
FY2025$70.3M
FY2026$62.6M

Largest awards collected

Award IDAgencyAmountStart
75N93018C00014Department of Health and Human Services$112.0MApr 13, 2018
75N93024C00003Department of Health and Human Services$95.8MMar 14, 2024
HHSN273201500012CDepartment of Health and Human Services$22.7MAug 24, 2015
HHSN272201800009CDepartment of Health and Human Services$16.0MMar 27, 2018
HHSN271201500083CDepartment of Health and Human Services$16.0MSep 11, 2015

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Insiders

· CEO & CFO Buying — Last 90 days: top executives (CEO/CFO) bought on the open market

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Key figures

· CEO & CFO Buying — Buy txns: 1 · Buy value: $3.0K · Insiders buying: 1 · Latest buy: Sep 30, 2026

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2023 Q4, ranked #38 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together30.0%-14.6%+3.4%-17.9%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold CRL — ranked by lift, the co-holding pattern described in Methodology: ICON PLC (ICLR) · IQVIA HOLDINGS INC. (IQV) · Medpace Holdings, Inc. (MEDP) · INCYTE CORP (INCY) · VSE CORP (VSEC) · Genpact LTD (G) · PAYCHEX INC (PAYX) · Booz Allen Hamilton Holding Corp (BAH).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 9, 20267.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Nov 4, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Sep 24, 20267.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

ICON PLC (ICLR) · Track Record: how the signals scored · Practice timing on CRL

One email a week: the week’s new filings and research. Subscribe free

← CRK  ·  CRM →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.